Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Median age and % Metastatic disease at presentation of SCCO, SCCO-HT, NET-O, and SCLC

From: Genomic alterations in neuroendocrine cancers of the ovary

Small Cell Cancer Type Median Age %Metastatic
SCCO (n = 10) 42 (12–75) 70 %
SCCO-HT (n = 18) 26 (8–40) 50 %
NET-O (n = 18) 62 (13–76) 33 %
SCLC (n = 58) 66 (36–86) 65 %